Listed

Sutro Biopharma, Inc.: Form 10-Q for the period ended Sep 30, 2018

Filed with the SEC on Nov 14, 2018 and accepted by EDGAR at Nov 14, 2018, 16:02 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2018-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development3 months2018-07-01 to 2018-09-30$12.6mus-gaap:ResearchAndDevelopmentExpense
Research and development9 months2018-01-01 to 2018-09-30$39.5mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2018-07-01 to 2018-09-30−$10.2mus-gaap:OperatingIncomeLoss
Operating income9 months2018-01-01 to 2018-09-30−$33.9mus-gaap:OperatingIncomeLoss
Interest expense3 months2018-07-01 to 2018-09-30$415.0kus-gaap:InterestExpense
Interest expense9 months2018-01-01 to 2018-09-30$1.2mus-gaap:InterestExpense
Net income3 months2018-07-01 to 2018-09-30−$10.2mus-gaap:NetIncomeLoss
Net income9 months2018-01-01 to 2018-09-30−$33.8mus-gaap:NetIncomeLoss
Diluted EPS3 months2018-07-01 to 2018-09-30−$21.26us-gaap:EarningsPerShareBasicAndDiluted
Diluted EPS9 months2018-01-01 to 2018-09-30−$71.06us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow9 months2018-01-01 to 2018-09-30$18.6mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure9 months2018-01-01 to 2018-09-30$759.0kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2018-09-30$41.4mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2018-09-30$127.4mus-gaap:AssetsCurrent
Total assetsAt period end2018-09-30$145.0mus-gaap:Assets
Current liabilitiesAt period end2018-09-30$36.9mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2018-09-30$99.2mus-gaap:Liabilities
Long-term debtAt period end2018-09-30$11.5mus-gaap:LongTermDebtNoncurrent
Current portion of debtAt period end2018-09-30$3.2mus-gaap:DebtCurrent
Shareholders' equityAt period end2018-09-30−$141.4mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001564590-18-029555. Last ingested by Listed: Nov 13, 2026, 16:35 ET. Listed shows no prices and gives no investment advice.